OncoCyte Corporation (AMEX: OCX) is 159.00% higher on its value in year-to-date trading and has touched a low of $1.15 and a high of $6.57 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The OCX stock was last observed hovering at around $6.34 in the last trading session, with the day’s loss setting it -0.15% off its average median price target of $7.00 for the next 12 months. It is also 43.73% off the consensus price target high of $11.00 offered by 5 analysts, but current levels are -23.8% lower than the price target low of $5.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $6.19, the stock is 10.28% and 58.89% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.3 million and changing -2.37% at the moment leaves the stock 163.06% off its SMA200. OCX registered 117.19% gain for a year compared to 6-month gain of 326.90%. The firm has a 50-day simple moving average (SMA 50) of $4.69 and a 200-day simple moving average (SMA200) of $2.42.
The stock witnessed a 31.98% loss in the last 1 month and extending the period to 3 months gives it a 253.71%, and is 4.56% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.92% over the week and 13.17% over the month.
OncoCyte Corporation (OCX) has around 33 employees, a market worth around $522.44M and $0.70M in sales. Distance from 52-week low is 438.26% and -5.78% from its 52-week high.
OncoCyte Corporation (OCX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for OncoCyte Corporation (OCX) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
OncoCyte Corporation is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at -$0.11 with sales reaching $820k over the same period.The EPS is expected to shrink by -5.00% this year.
OncoCyte Corporation (OCX) Top Institutional Holders
83 institutions hold shares in OncoCyte Corporation (OCX), with 10.58M shares held by insiders accounting for 15.73% while institutional investors hold 54.90% of the company’s shares. The shares outstanding are 67.25M, and float is at 36.33M with Short Float at 5.48%. Institutions hold 46.27% of the Float.
The top institutional shareholder in the company is Broadwood Capital, Inc. with over 14.72 million shares valued at $20.46 million. The investor’s holdings represent 21.88% of the OCX Shares outstanding. As of Sep 29, 2020, the second largest holder is Pura Vida Investments, LLC with 6.02 million shares valued at $8.37 million to account for 8.96% of the shares outstanding. The other top investors are Blackrock Inc. which holds 3.5 million shares representing 5.21% and valued at over $8.37 million, while Vanguard Group, Inc. (The) holds 2.86% of the shares totaling 1.92 million with a market value of $2.67 million.
OncoCyte Corporation (OCX) Insider Activity
A total of 18 insider transactions have happened at OncoCyte Corporation (OCX) in the last six months, with sales accounting for 4 and purchases happening 14 times. The most recent transaction is an insider purchase by BROADWOOD PARTNERS, L.P., the company’s 10% Owner. SEC filings show that BROADWOOD PARTNERS, L.P. bought 600,000 shares of the company’s common stock on Feb 05 at a price of $4.50 per share for a total of $2.7 million. Following the purchase, the insider now owns 16.78 million shares.
OncoCyte Corporation disclosed in a document filed with the SEC on Jan 20 that BROADWOOD PARTNERS, L.P. (10% Owner) bought a total of 1,460,280 shares of the company’s common stock. The trade occurred on Jan 20 and was made at $3.42 per share for $5.0 million. Following the transaction, the insider now directly holds 16.18 million shares of the OCX stock.
Still, SEC filings show that on Dec 23, KINGSLEY ALFRED D (Director) disposed off 900 shares at an average price of $2.55 for $2295.0. The insider now directly holds 318,840 shares of OncoCyte Corporation (OCX).
OncoCyte Corporation (OCX): Who are the competitors?
Omeros Corporation (OMER) is 61.81% up on the 1-year trading charts. Short interest in the company’s stock has fallen -25.63% from the last report on Dec 30, 2020 to stand at a total of 2.5 million short shares sold with a short interest ratio of 1.2.